Drug Shrinks Belly Fat and Liver Fat in HIV Patients
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A drug called tesamorelin helps reduce belly fat and fat in the liver in people with HIV who have too much belly fat. It works by making the body produce more growth hormone. The fat loss is real, but blood sugar goes up a little at first, then returns to normal.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 573 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A drug called tesamorelin helps reduce belly fat and fat in the liver in people with HIV who have too much belly fat. It works by making the body produce more growth hormone. The fat loss is real, but blood sugar goes up a little at first, then returns to normal.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 573 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Authors
Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK
Related Content
Claims (9)
Visceral fat is metabolically active tissue that disrupts insulin sensitivity and metabolic function, and tesamorelin reduces it through mechanisms that improve fat quality, muscle composition, and mitochondrial efficiency, leading to long-term metabolic resilience.
A hormone treatment called tesamorelin lowers liver enzyme levels by 4 units more than a placebo in people with HIV after six months of treatment.
A hormone treatment called tesamorelin raises IGF-1 hormone levels more than a placebo in people with HIV at 2 weeks, 3 months, and 6 months of treatment.
A hormone treatment called tesamorelin decreases belly fat by 42 square centimeters more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.
A hormone treatment called tesamorelin doesn't change the fat under the skin in people with HIV who have excess belly fat after six months of treatment.